New radiation therapy targets kidney cancer cells

NCT ID NCT07197580

Recruiting now Disease control Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests a drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for adults with advanced clear cell kidney cancer that has returned or spread after prior treatments. The study first finds the best dose, then compares it to standard single-drug therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lutetium (177Lu) girentuximab tetraxetan (a targeted radiation therapy)
What this could lead to: If successful, this could offer a new treatment option for people with advanced clear cell kidney cancer that has come back or spread.
What could go wrong: This is an early-stage dose-finding study with only 40 participants, so results may not apply broadly. The treatment involves radiation and could cause side effects like fatigue or blood cell changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CCRCC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma kidney cancer nonpapillary renal cell carcinoma Recurrence renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CCRCC CLEAR CELL RENAL CELL CANCER (CCRCC) RENAL CELL CANCER METASTATIC RENAL CELL CANCER, RECURRENT RENAL CELL CARCINOMA (KIDNEY CANCER) RENAL CELL CARCINOMA (RCC)

Contacts and locations

Locations

Austin Health
NOT_YET_RECRUITING

Heidelberg, Victoria, 3084, Australia
GenesisCare, Fiona Stanley Hospital (Murdoch)
RECRUITING

Murdoch, Washington, 6150, Australia
Melbourne Theranostic Innovation Centre (MTIC)
NOT_YET_RECRUITING

Melbourne N., Victoria, 3051, Australia
Westmead Hospital
NOT_YET_RECRUITING

Sydney, New South Wales, 2145, Australia
Wollongong Hospital
NOT_YET_RECRUITING

Wollongong, New South Wales, 2500, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.